article thumbnail

Scientists reveal structural details of how SARS-CoV-2 variants escape immune response

Scienmag

The findings provide direction for future vaccines or therapies that may offer broader protection against variants LA JOLLA, CA–Fast-spreading variants of the COVID-19-causing coronavirus, SARS-CoV-2, carry mutations that enable the virus to escape some of the immune response created naturally or by vaccination.

article thumbnail

Delaying second dose of mRNA COVID-19 vaccine produces stronger immune response

The Pharma Data

The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada through its COVID-19 Immunity Task Force (CITF).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pfizer/BioNTech vaccine may work against new virus mutation, scientists say

pharmaphorum

The Pfizer/BioNTech vaccine appears to work against an important mutation in the new coronavirus variants causing havoc in the UK and South Africa, according to research from the drugs giant. The study team tested blood taken from people who had received the mRNA vaccine developed by BioNTech and Pfizer.

Scientist 124
article thumbnail

Discovery of 'Goldilocks' effect of nanoparticles offers significant hope for improved vaccines

Medical Xpress

Scientists have discovered there is a "Goldilocks" effect in identifying the size of a "vaccine adjuvant" that can trigger strong immune responses and, as an example, have shown that a safe, biodegradable adjuvant can boost the action of cancer-killing cells—if the particles are the correct size.

article thumbnail

Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

The Pharma Data

The study assessed cynomolgus macaques vaccinated with 12µg of either the first or second-generation vaccine candidate. During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages.

article thumbnail

Moderna’s HIV vaccine prepped for trials in Africa

pharmaphorum

Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt. There are hopes that its mRNA approach, which proved so effective against COVID-19, could succeed where traditional vaccine technologies have failed in HIV.

article thumbnail

CMV Vaccine Trials: Moderna’s CMV mRNA Vaccine Enters Phase III

XTalks

Moderna has been testing an experimental mRNA vaccine aimed at combating the human cytomegalovirus (CMV), which poses significant health risks to newborns and immunocompromised patients. The team used the data and patient samples from a gB/MF59 Phase II trial in adolescent girls as a benchmark to assess the new mRNA-based vaccine.